Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02451579 · ClinicalTrials.gov registry record · NA
A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy
A NA study of Actinic Keratoses, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02451579 is a NA study of Actinic Keratoses that has completed, run by Goldman, Butterwick, Fitzpatrick and Groff. The registered enrollment target is 20 participants, below the 96-participant average among 12 other Actinic Keratoses trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02451579, a NA study of Actinic Keratoses, has completed, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
A double-blind, placebo controlled study conducted at a single study site. Evaluating the role of systemic antihistamine therapy in the reduction of adverse effects associated with topical 5-aminolevulinic acid photodynamic therapy.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Antihistamine Cetirizine Hydrochloride
Study Locations (1)
California
- Cosmetic Laser Dermatology - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-02 |
| Est. Completion | 2017-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02451579
The ClinicalTrials.gov registry entry for NCT02451579 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 96-participant average among 12 other Actinic Keratoses trials with a reported enrollment target (79% lower). The listed sponsor is Goldman, Butterwick, Fitzpatrick and Groff, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Actinic Keratoses appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02451579 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02451579 about?
NCT02451579 is a clinical study titled "A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy". A double-blind, placebo controlled study conducted at a single study site. Evaluating the role of systemic antihistamine therapy in the reduction of adverse effects associated with topical 5-aminolevulinic acid photodynamic therapy.
What is the current status of trial NCT02451579?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2015-02. Estimated completion is 2017-01.
What conditions does trial NCT02451579 study?
This clinical trial studies the following conditions: Actinic Keratoses.
What interventions are being tested in trial NCT02451579?
The interventions under investigation include: Placebo (OTHER), Antihistamine Cetirizine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02451579?
This trial is sponsored by Goldman, Butterwick, Fitzpatrick and Groff, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02451579 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Actinic Keratoses
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effectiveness of Fractionated Laser Resurfacing to Protect Geriatric Skin From Actinic Neoplasia
RECRUITING · NA
-
The Preventive Role of Fractionated Laser Resurfacing Against Actinic Neoplasia in an At-Risk Geriatric Population
RECRUITING · NA
-
Photodynamic Therapy Incubation Times for Actinic Keratosis
ACTIVE NOT RECRUITING · NA
-
Continuous Quality Improvement (CQI) Pilot Study Evaluating the Utility of an Educational Video
COMPLETED · NA
-
A Photodynamic Therapy for Treatment of Actinic Keratoses
COMPLETED · NA
-
Cryotherapy in Combination with Red Light PDT for Actinic Keratosis of Full Face
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.